Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages [RNA-seq]

ABSTRACT: TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages [RNA-seq]

PROVIDER: PRJNA1069090 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27729433_1.fastq.gz	Fastqsanger.gz
	SRR27729433_2.fastq.gz	Fastqsanger.gz
	SRR27729434_1.fastq.gz	Fastqsanger.gz
	SRR27729434_2.fastq.gz	Fastqsanger.gz
	SRR27729435_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages

Project description:TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages

| PRJNA540686 | ENA

TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages

Project description:TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages

| PRJNA827343 | ENA

TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages

Project description:The Liver X receptors (LXRα and LXRβ) are members of the nuclear receptor superfamily of transcription factors, and play key roles in the coordination of both metabolic and immune responses in macrophages. Both LXRs are expressed in macrophages and they share a high degree of sequence homology but their individual roles in different models of macrophage cultures, particularly in response to inflammation, have not been characterized. Previous studies have shown that ligand pre-treated LXRs repress the induction of pro-inflammatory cytokines in macrophages. Here, we show evidence that the expression of LXRα (but not LXRβ) is transcriptionally regulated at late phases of an LPS-induced inflammatory response in bone marrow-derived macrophages (BMDMs). Regulation of LXRα expression is controlled at the transcriptional levels by inflammatory signaling networks. Transcriptional profiling studies and ChIP-seq data identified a number of innate immune pathways whose expression is substantially controlled by LXRα in BMDMs. In summary, our data shows that LXRα plays a previously unrecognized role in innate immunity by transcriptional regulation of a battery of inflammatory genes through TLR and Type-I IFN-dependent signaling in macrophages.

2022-12-31 | GSE200922 | GEO

TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages

2020-05-01 | GSE130586 | GEO

TLR-dependent transcriptional reprogramming of LXRα cistrome in bone marrow-derived macrophages [RNA-seq]

2024-04-02 | GSE254257 | GEO

Effect of cell-penetrating TLR decoy peptide on LPS-stimulated Bone marrow derived macrophages

Project description:To investigate the effects of the cell-penetrating TLR decoy peptide, M-CSF generated bone marrow derived macrophages obtained from C57BL6/J mice were pretreated with two different concentrations of the peptide followed by stimulation with LPS for 2 hours. The cells were lyzed and analyzed by RNA Sequencing.

2023-02-10 | GSE224903 | GEO

Next Generation Sequencing of LdlrKO LXRα-phosphorylation disrupted macrophage transcriptomes

Project description:Liver X Receptors (LXRα and β) are ligand-activated transcription factors that play a key role in the control of lipid homeostasis, as well as modulation of immunity and inflammation. Besides ligand binding, LXR activity can be regulated by posttranslational modifications, such as phosphorylation. This study aims to assess changes in bone marrow derived macrophage transcriptional profiles of mice that carry LysMcre directed phosphorylation deficient-version of LXRα compared (S196A) to wild-type (WT).

2018-06-29 | GSE112213 | GEO

Foam cell specific LXRα ligand

Project description:OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoid structure (STX4) in order to reach nanomolar effective concentrations in LXRα reporter-gene assays. STX4 displayed the unique property to activate LXRα effectively but not its subtype LXRβ. The potential of STX4 to increase transcriptional activity as an LXRα ligand was tested with gene expression analyses in THP1-derived human macrophages and oxLDL-loaded human foam cells. Only in foam cells but not in macrophage cells STX4 treatment showed athero-protective effects with similar potency as the synthetic LXR ligand T0901317 (T09). Surprisingly, combinatorial treatment with STX4 and T09 resulted in an additive effect on reporter-gene activation and target gene expression. In physiological tests the cellular content of total and esterified cholesterol was significantly reduced by STX4 without the undesirable increase in triglyceride levels as observed for T09. CONCLUSIONS: STX4 is a new LXRα-ligand to study transcriptional regulation of anti-atherogenic processes in cell or ex vivo models, and provides a promising lead structure for pharmaceutical development.

2013-09-05 | GSE39079 | GEO

Effect of cell-penetrating TLR decoy peptide on LPS-stimulated Bone marrow derived macrophages

Project description:Effect of cell-penetrating TLR decoy peptide on LPS-stimulated Bone marrow derived macrophages

| PRJNA933088 | ENA

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Project description:RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.

| 2004880 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data